Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.37 |
| ▸ | ITPR3 | Q14573 | 8/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.31 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165319 | 0.84 | INPP5A (0.37) | INPP5AITPR3ENO1SMPD1ITPR2 | |
| SCHEMBL252069 | 0.84 | INPP5A (0.37) | GAAINPP5AITPR3ENO1SMPD1 | |
| SCHEMBL13227476 | 0.84 | GAA (0.38) | GAAHTTL3MBTL1KDM4EENO1 | |
| SCHEMBL13120880 | 0.84 | GAA (0.38) | GAAHTTL3MBTL1KDM4EENO1 | |
| SCHEMBL15951384 | 0.83 | GAA (0.35) | GAAHTTL3MBTL1KDM4EENO1 | |
| SCHEMBL23343537 | 0.82 | GAA (0.37) | GAAHTTL3MBTL1KDM4EKMT2A | |
| Water SCHEMBL2026850 | 0.82 | INPP5A (0.36) | INPP5AITPR3SMPD1ITPR2ITPR1 | |
| SCHEMBL14409850 | 0.81 | INPP5A (0.35) | INPP5AITPR3SMPD1KMT2AALDH1A1 | |
| SCHEMBL29389192 | 0.81 | INPP5A (0.35) | INPP5AITPR3SMPD1KMT2AALDH1A1 | |
| SCHEMBL14372135 | 0.81 | GAA (0.36) | GAAHTTL3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627345-A1 | MEASUREMENT OF REACTIVE OXYGEN SPECIES TO ASSESS RED BLOOD CELL QUALITY | University Of Maryland, Baltimore (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250298040-A1 | MEASUREMENT OF REACTIVE OXYGEN SPECIES TO ASSESS RED BLOOD CELL QUALITY | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-09-25 | — | — | US | claimed |
| WO-2024119059-A1 | MEASUREMENT OF REACTIVE OXYGEN SPECIES TO ASSESS RED BLOOD CELL QUALITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-06-06 | — | — | WO | claimed |
| CN-115710701-A | Chemical gold plating solution and application | 广东东硕科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| WO-2022251679-A1 | NITROXIDE RADICALS FOR USE AS ANTIVIRAL TREATMENT FOR CORONAVIRUS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-01 | — | — | WO | claimed |
| US-10245256-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | claimed |
| US-20170095459-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | Knobbe, Martens, Olson & Bear, LLP | 2017-04-06 | — | — | US | claimed |
| US-9522144-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | claimed |
| US-9522143-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | claimed |
| US-9475916-B2 | Process for curing surface-coating compositions | ALLNEX AUSTRIA GMBH (AT) | 2016-10-25 | — | — | US | claimed |
| EP-2655527-A1 | PROCESS FOR CURING SURFACE-COATING COMPOSITIONS | ALLNEX AUSTRIA GmbH (AT) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085016-A1 | PROCESS FOR CURING SURFACE-COATING COMPOSITIONS | CYTEC AUSTRIA GMBH (AT) | 2012-06-28 | — | — | WO | claimed |
| WO-2012021453-A2 | EVALUATING ANTI-INFLAMMATORY RESPONSES | MELALEUCA, INC. (US) | 2012-02-16 | — | — | WO | claimed |
| EP-2324045-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | Cornell University (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010017264-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | CORNELL UNIVERSITY (US) | 2010-02-11 | — | — | WO | claimed |
| WO-2008062210-A2 | FREE RADICAL TRAPPING | THE UNIVERSITY OF SALFORD (GB) | 2008-05-29 | — | — | WO | claimed |
| EP-0983334-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | Call, Krimhild (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1999001607-A2 | ENZYMATIC OXIDATION SYSTEM WITH NOVEL ENZYMATIC-EFFECT ENHANCING COMPOUNDS | CALL, KRIMHILD (DE) | 1999-01-14 | — | — | WO | claimed |
| WO-1998055684-A1 | MULTI-COMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, MATERIALS CONTAINING LIGNIN OR SIMILAR SUBSTANCES AND METHODS FOR PRODUCING THE SAME | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-10 | — | — | WO | claimed |
| WO-1998051772-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | CALL, KRIMHILD (DE) | 1998-11-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245256-B2 | Nitroxides for use in treating or preventing diabetes and obesity | TXNRD2, TXN2, TET1 | GAA 2772/4885HTT 1248/4885L3MBTL1 850/4885 |
| US-20170095459-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | TXNRD2, TXN2, TET1 | GAA 2772/4885HTT 1248/4885L3MBTL1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.